Cargando…

Anti-GD2 CAR T cells could prove transformative for H3-K27M(+) diffuse midline gliomas

Detalles Bibliográficos
Autores principales:	Furukawa, Koichi, Ohmi, Yuhsuke, Furukawa, Keiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797336/ https://www.ncbi.nlm.nih.gov/pubmed/35117070 http://dx.doi.org/10.21037/tcr.2018.08.21

Ejemplares similares

Erratum to anti-GD2 CAR T cells could prove transformative for H3-K27M(+) diffuse midline gliomas
por: Furukawa, Koichi, et al.
Publicado: (2019)

GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas
por: Majzner, Robbie G., et al.
Publicado: (2022)

Disordered testosterone transport in mice lacking the ganglioside GM2/GD2 synthase gene
por: Furukawa, Koichi, et al.
Publicado: (2023)

Potent antitumor efficacy of anti-GD2 CAR T-cells in H3K27M+ diffuse midline gliomas
por: Mount, Christopher W., et al.
Publicado: (2018)

Lack of GD3 synthase (St8sia1) attenuates malignant properties of gliomas in genetically engineered mouse model
por: Ohkawa, Yuki, et al.
Publicado: (2021)

ASC amino acid transporter 2, defined by enzyme‐mediated activation of radical sources, enhances malignancy of GD2‐positive small‐cell lung cancer
por: Esaki, Nobutoshi, et al.
Publicado: (2018)

Extracellular vesicles released from ganglioside GD2-expressing melanoma cells enhance the malignant properties of GD2-negative melanomas
por: Yesmin, Farhana, et al.
Publicado: (2023)

IMMU-18. TARGETING GD2 IN THALAMIC DIFFUSE MIDLINE GLIOMA WITH TRANSIENT MRNA CAR T CELLS
por: Foster, Jessica, et al.
Publicado: (2023)

Ganglioside GM3 prevents high fat diet-induced hepatosteatosis via attenuated insulin signaling pathway
por: Tajima, Orie, et al.
Publicado: (2023)

IMMU-22. Safely targeting GD2 in thalamic diffuse midline glioma with mRNA CAR T cells
por: Foster, Jessica, et al.
Publicado: (2022)

MRI comparative study of diffuse midline glioma, H3 K27-altered and glioma in the midline without H3 K27-altered
por: Zhao, Ji-ping, et al.
Publicado: (2022)

IMMU-17. USE OF MRNA FOR SAFE AND EFFECTIVE GD2-DIRECTED CAR T CELLS TO TREAT DIFFUSE MIDLINE GLIOMAS
por: Foster, Jessica, et al.
Publicado: (2021)

Ganglioside deficiency causes inflammation and neurodegeneration via the activation of complement system in the spinal cord
por: Ohmi, Yuhsuke, et al.
Publicado: (2014)

Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins
por: Yesmin, Farhana, et al.
Publicado: (2021)

IMMU-13. DUAL IGF1R/IR INHIBITOR IN COMBINATION WITH GD2-CAR T-CELLS AS A POTENT THERAPEUTIC STRATEGY FOR H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS
por: de Billy, Emmanuel, et al.
Publicado: (2020)

Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant
por: de Billy, Emmanuel, et al.
Publicado: (2021)

DIPG-15. Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T-cells
por: Monje, Michelle, et al.
Publicado: (2022)

Disruption of GM2/GD2 synthase gene resulted in overt expression of 9-O-acetyl GD3 irrespective of Tis211
por: Furukawa, Keiko, et al.
Publicado: (2008)

Fatal Postpartum Hemorrhage in Diffuse Midline Glioma with H3-K27M Mutation
por: Miyazaki, Takeshi, et al.
Publicado: (2019)

DIPG-42. Diffuse midline gliomas, H3K27-altered as an interdisciplinary challenge
por: Kammler, Gertrud, et al.
Publicado: (2022)

Radiotherapy and radio‐sensitization in H3 (K27M) ‐mutated diffuse midline gliomas
por: Liu, Chao, et al.
Publicado: (2023)

A H3K27M-targeted vaccine in adults with diffuse midline glioma
por: Grassl, Niklas, et al.
Publicado: (2023)

Expression of B4GALNT1, an essential glycosyltransferase for the synthesis of complex gangliosides, suppresses BACE1 degradation and modulates APP processing
por: Yamaguchi, Tokiaki, et al.
Publicado: (2016)

Differential roles of gangliosides in malignant properties of melanomas
por: Ohmi, Yuhsuke, et al.
Publicado: (2018)

Differences in the MRI Signature and ADC Values of Diffuse Midline Gliomas with H3 K27M Mutation Compared to Midline Glioblastomas
por: Raab, Peter, et al.
Publicado: (2022)

Elucidation of the enigma of glycosphingolipids in the regulation of inflammation and degeneration — Great progress over the last 70 years —
por: FURUKAWA, Koichi, et al.
Publicado: (2019)

Absence of MGMT promoter methylation in diffuse midline glioma, H3 K27M-mutant
por: Banan, Rouzbeh, et al.
Publicado: (2017)

Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas
por: Welby, John P., et al.
Publicado: (2019)

Morphological Spectrum and Survival Analysis of Diffuse Midline Glioma With H3K27M Mutation
por: Hassan, Usman, et al.
Publicado: (2021)

Diffuse midline glioma H3K27M mutation in adult: A case report
por: Bhattarai, Ayush Mohan, et al.
Publicado: (2022)

Diffuse midline glioma with H3 K27M-mutation in an 83-year-old woman
por: Low, Justin Thomas, et al.
Publicado: (2021)

Deep Learning for the Prediction of the Survival of Midline Diffuse Glioma with an H3K27M Alteration
por: Huang, Bowen, et al.
Publicado: (2023)

ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
por: Jackson, Evangeline R., et al.
Publicado: (2023)

St8sia1-deficiency in mice alters tumor environments of gliomas, leading to reduced disease severity
por: Zhang, Pu, et al.
Publicado: (2021)

New era of research on cancer‐associated glycosphingolipids
por: Furukawa, Koichi, et al.
Publicado: (2019)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas
por: Abe, Hideaki, et al.
Publicado: (2020)

Exploiting Gangliosides for the Therapy of Ewing’s Sarcoma and H3K27M-Mutant Diffuse Midline Glioma
por: Wingerter, Arthur, et al.
Publicado: (2021)

DIPG-44. H3K27-altered diffuse midline gliomas with secondary driver molecular alterations
por: Gestrich, Catherine, et al.
Publicado: (2022)

A validated prognostic nomogram for patients with H3 K27M-mutant diffuse midline glioma
por: Peng, Youheng, et al.
Publicado: (2023)

Diffuse midline gliomas, H3 K27M-mutant are associated with less peritumoral edema and contrast enhancement in comparison to glioblastomas, H3 K27M-wildtype of midline structures
por: Banan, Rouzbeh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_43u6id58ifcfl12c0m9704kv4n